Hemophilia A Gene Therapy- KOL Insights – Complete Report- Mellalta Meets 2020

 
NEW YORK - Aug. 21, 2020 - PRLog -- Market adoption of gene therapy in haemophilia A is still a cause for concern due to the expected high prices, durability issues, redosing, safety concerns and key unknown factors that are still under discussion. Establishing a new modality of treatment in any disease space has many proven challenges, but what if it offered a real cure?

Gene therapy in haemophilia can influence treatment practices, reduce treatment burden, and chronic drug delivery in patients whilst providing cure. But how bright is the future for hemophilia gene therapy for hematologists and gene therapy experts and what are their critical questions that would help pharmaceutical and biotech companies develop better market access strategies?

What to expect

A detailed report exploring, through Haematologist and gene therapy experts' insights, how gene therapy in Hemophilia is driving new thinking and solutions:

• An examination of key issues that are shaping approaches to the adoption of gene therapy in hemophilia
• 30 targeted questions put to gene therapy experts
• Their responses which provided 14 interviews supported by 50 directly quoted comments

Hemophilia A gene therapy key findings

This Hemophilia A Gene Therapy KOLs insight deck for Hemophilia A provides the high level analysis surrounding the KOLs viewpoint from the US and Europe region

Clinical perspective
Commercial Perspective
Payer perspective

Hemophilia A Gene Therapy –Key Questions Answered

Clinical Perspective


• How do we compare them on the results of various gene therapy clinical trials?
• What is the expected duration of the effects of gene therapy? Will they be permanent or transient?
To be Continued…

Commercial Perspective

• How much segment of the haemophilia market will be occupied by gene therapy?
• How difficult do you think it is for patients to move from factor replacement to gene therapy?
• Will Hemlibra patients also consider switching?
To be Continued…

Payer Perspective

• Are doctors excited about gene therapy or it's still a matter of concern for them to prescribe to the patients?
• Reimbursement and Negotiations with Payers
To be Continued….

Participating KOLs -14 KOLs Interviewed

Gene therapy Researcher

• Haematologist, Children's Hospital of Philadelphia, US

Medical Director, Special Haemostasis Laboratory & Associate Director

• Hemophilia Treatment Centre, Washington, United States

Faculty, Health Sciences

• University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa

Honorary Consultant Haematologist, Centre Director

• Royal London Hospital Hemophilia Centre, Arts Health NHS Trust, UK

KOLs

• Irish Haemophilia Society, Ireland

To be Continued……

Buy the Report by clicking the link: https://mellalta.com/product/hemophilia-a-gene-therapy-key-opinion-leaders-kols-insight-an-executive-report-2020/  [Special discount available]
End
Email:***@mellalta.com Email Verified
Tags:Hemophilia
Industry:Health
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Mellalta Meets News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share